<DOC>
	<DOCNO>NCT02045602</DOCNO>
	<brief_summary>The purpose study determine safety tolerability VCN-01 either administer alone combination Abraxane®/Gemcitabine , determine recommend phase II dose VCN-01 alone combination Abraxane®/Gemcitabine .</brief_summary>
	<brief_title>Phase I Dose Escalation Study Intravenous VCN-01 With Without Gemcitabine Abraxane® Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The study consist three part : - Part I dose escalation study determine safety tolerability single intravenous injection VCN-01 alone - In Part II safety tolerability two high VCN-01 tolerable dos part I evaluate combination Abraxane®/Gemcitabine . - In Part III safety tolerability two high VCN-01 tolerable dos part I evaluate combination Abraxane®/Gemcitabine `` delay '' schedule compare Part II .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Male/Female patient age 18 year Patients must provide write informed consent Part I : Patients histologically confirm , locally advanced metastatic solid tumor . Part II Part III : Patients histologically confirm , pancreatic adenocarcinoma establish therapy Abraxane®/Gemcitabine ( clinical standard care ) Life expectancy 3 month Patients willing comply treatment followup ECOG Performance status 0 1 Adequate baseline organ function ( hematologic , liver , renal nutritional ) Use reliable method contraception fertile men woman Active infection serious illness autoimmune disease Treatment live attenuate vaccine last three week Known chronic liver disease ( liver cirrhosis , chronic hepatitis ) Treatment another investigational agent within five halflives prior VCN01 infusion Viral syndrome diagnose two week inclusion Chronic immunosuppressive therapy Concurrent malignant hematologic solid disease Pregnancy lactation . Patients must agree use effective contraception surgically sterile . Patients receive fulldose anticoagulant / antiplatelet therapy Adequate level neutralize antibody adenovirus Patients Li Fraumeni syndrome previous know retinoblastoma protein pathway germinal deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oncolytic virus</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Pancreatic cancer</keyword>
</DOC>